186 related articles for article (PubMed ID: 24264229)
1. Cell intrinsic and extrinsic factors synergize in mice with haploinsufficiency for Tp53, and two human del(5q) genes, Egr1 and Apc.
Stoddart A; Wang J; Fernald AA; Karrison T; Anastasi J; Le Beau MM
Blood; 2014 Jan; 123(2):228-38. PubMed ID: 24264229
[TBL] [Abstract][Full Text] [Related]
2. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
Stoddart A; Fernald AA; Wang J; Davis EM; Karrison T; Anastasi J; Le Beau MM
Blood; 2014 Feb; 123(7):1069-78. PubMed ID: 24381225
[TBL] [Abstract][Full Text] [Related]
3. Haploinsufficiency of Apc leads to ineffective hematopoiesis.
Wang J; Fernald AA; Anastasi J; Le Beau MM; Qian Z
Blood; 2010 Apr; 115(17):3481-8. PubMed ID: 20065296
[TBL] [Abstract][Full Text] [Related]
4. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.
Joslin JM; Fernald AA; Tennant TR; Davis EM; Kogan SC; Anastasi J; Crispino JD; Le Beau MM
Blood; 2007 Jul; 110(2):719-26. PubMed ID: 17420284
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms.
Stoddart A; Wang J; Fernald AA; Davis EM; Johnson CR; Hu C; Cheng JX; McNerney ME; Le Beau MM
Blood Cancer Discov; 2020 Jul; 1(1):32-47. PubMed ID: 32924016
[TBL] [Abstract][Full Text] [Related]
6. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
Ebert BL
Semin Oncol; 2011 Oct; 38(5):621-6. PubMed ID: 21943668
[TBL] [Abstract][Full Text] [Related]
7. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
Hosono N; Makishima H; Mahfouz R; Przychodzen B; Yoshida K; Jerez A; LaFramboise T; Polprasert C; Clemente MJ; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Sanada M; Cui E; Verma AK; McDevitt MA; List AF; Saunthararajah Y; Sekeres MA; Boultwood J; Ogawa S; Maciejewski JP
Oncotarget; 2017 Jan; 8(4):6483-6495. PubMed ID: 28031539
[TBL] [Abstract][Full Text] [Related]
8. EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy.
Stoddart A; Fernald AA; Davis EM; McNerney ME; Le Beau MM
Exp Hematol; 2022 Nov; 115():54-67. PubMed ID: 35995095
[TBL] [Abstract][Full Text] [Related]
9. Deletion 5q MDS: molecular and therapeutic implications.
Komrokji RS; Padron E; Ebert BL; List AF
Best Pract Res Clin Haematol; 2013 Dec; 26(4):365-75. PubMed ID: 24507813
[TBL] [Abstract][Full Text] [Related]
10. β-Catenin Is a Candidate Therapeutic Target for Myeloid Neoplasms with del(5q).
Li L; Sheng Y; Li W; Hu C; Mittal N; Tohyama K; Seba A; Zhao YY; Ozer H; Zhu T; Qian Z
Cancer Res; 2017 Aug; 77(15):4116-4126. PubMed ID: 28611040
[TBL] [Abstract][Full Text] [Related]
11. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
Lane SW; Sykes SM; Al-Shahrour F; Shterental S; Paktinat M; Lo Celso C; Jesneck JL; Ebert BL; Williams DA; Gilliland DG
Blood; 2010 Apr; 115(17):3489-97. PubMed ID: 20197553
[TBL] [Abstract][Full Text] [Related]
12. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
[TBL] [Abstract][Full Text] [Related]
13. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
Mei Y; Zhao B; Basiorka AA; Yang J; Cao L; Zhang J; List A; Ji P
Leukemia; 2018 Apr; 32(4):1023-1033. PubMed ID: 29263441
[TBL] [Abstract][Full Text] [Related]
14. 5q- syndrome.
Boultwood J; Pellagatti A; Wainscoat JS
Curr Pharm Des; 2012; 18(22):3180-3. PubMed ID: 22571696
[TBL] [Abstract][Full Text] [Related]
15. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.
Lee JH; List A; Sallman DA
Eur J Haematol; 2019 Mar; 102(3):203-209. PubMed ID: 30578738
[TBL] [Abstract][Full Text] [Related]
17. Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.
Adema V; Palomo L; Walter W; Mallo M; Hutter S; La Framboise T; Arenillas L; Meggendorfer M; Radivoyevitch T; Xicoy B; Pellagatti A; Haferlach C; Boultwood J; Kern W; Visconte V; Sekeres M; Barnard J; Haferlach T; Solé F; Maciejewski JP
EBioMedicine; 2022 Jun; 80():104059. PubMed ID: 35617825
[TBL] [Abstract][Full Text] [Related]
18. Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
Ribezzo F; Snoeren IAM; Ziegler S; Stoelben J; Olofsen PA; Henic A; Ferreira MV; Chen S; Stalmann USA; Buesche G; Hoogenboezem RM; Kramann R; Platzbecker U; Raaijmakers MHGP; Ebert BL; Schneider RK
Leukemia; 2019 Jul; 33(7):1759-1772. PubMed ID: 30651631
[TBL] [Abstract][Full Text] [Related]
19. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
20. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
